Evaluate Effects of Personalized Patient Counselling for Enbrel® Therapy in Adults With Rheumatoid Arthritis

Phase 4

Terminated

• Conditions: Persistence to Enbrel
• Interventions: Behavioral: Personalized Patient Counselling

• Registration Number: NCT02346877
• Lead Sponsor: Amgen

Brief Summary

This study will evaluate whether the effect of personalized patient counselling tool, Information-Motivation-Strategy (IMS) based on the results of the Beliefs about Medicines Questionnaire (BMQ) will improve persistence of Enbrel (etanercept) therapy at week 52 in subjects with rheumatoid arthritis over the historical control as estimated by the standard of care.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2015-01-07
• Study First Submitted QC: 2015-01-21
• Study First Posted: 2015-01-27
• Study Start: 2015-04
• Primary Completion: 2015-10
• Study Completion: 2015-10
• Results First Submitted: 2016-10-20
• Status Verified: 2017-03
• Results First Submitted QC: 2017-03-23
• Last Update Submitted: 2017-03-23
• Results First Posted: 2017-03-27
• Last Update Posted: 2017-03-27

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 19

Inclusion Criteria

• Subject has provided informed consent prior to any study specific procedures
• diagnosed with rheumatoid arthritis and eligible for treatment with Enbrel® (etanercept)
• Subject has been prescribed and has access to commercial Enbrel® (etanercept) (50mg once weekly) according to the subject's health insurance
• Completion of all required safety assessments before starting treatment with Enbrel® (etanercept)

Other Inclusion Criteria May apply.

Exclusion Criteria

• previously received treatment with a biologic disease modifying antirheumatic drug (DMARD) and/or Tofacitinib.
• Malignancy (except nonmelanoma skin cancers, cervical or breast ductal carcinoma in situ) within the last 5 years
• refusal to consent to enroll in the Enliven program
• Currently receiving treatment in another investigational device or drug study, or less than 30 days since ending treatment on another investigational device or drug study(s)

Other Exclusion Criteria May Apply.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Personalized Patient Counselling Cohort	Personalized Patient Counselling	Initiation of the personalized patient counselling cohort will begin after 75% of participants in the control cohort have been analyzed and shown not to have high persistence. Participants will receive Enbrel® (etanercept) therapy in routine clinical practice and personalized patient counselling based on the Information-Motivation-Strategy (IMS) model based on Beliefs about Medicines Questionnaire (BMQ) baseline results through a patient assistance program for patients on Enbrel (etanercept) therapy.

Primary Outcome Measures

Name	Time	Method
Persistence of Study Drug Measured at 52 Weeks	52 weeks	A participant is persistent if the date of the last prescription filled plus the number of weeks supply of the prescription is greater than or equal to 52 weeks from enrolment and the eDiary confirms Enbrel® from the prescription was injected. A participant is not persistent if the last prescription filled plus the number of weeks supply of the prescription is less than 52 weeks from enrolment and the eDiary confirms there was no injection of Enbrel®, or, a participant is not persistent if the participant has a gap in treatment of more than 4 consecutive weeks for no medical reason at any time in the 52 week study period.

Secondary Outcome Measures

Name	Time	Method
Adherence to Study Drug up to 52 Weeks	52 weeks	A participant's adherence is determined as a medication possession ratio (MPR) of at least 80%. The MPR is the ratio of the total number of weeks' supply, based on pharmacy data, of Enbrel® divided by either 52 weeks or duration on study if a physician stops prescribing Enbrel® due to an adverse drug reaction or lack of efficacy.
Beliefs About Medicines Questionnaire (BMQ)	52 weeks	BMQ consists of two five-item scales assessing patients' beliefs about the necessity of Enbrel® for controlling their rheumatoid arthritis and their concerns about potential adverse consequences of taking Enbrel®. Using a five-point Likert scale, on each of necessity and concerns, the individual items within both scales are summed. The total scores for the Necessity and Concerns Scales range from 5 to 25. Higher scores indicate stronger beliefs.

Trial Locations

Locations (1)

Research Site; 🇨🇦 Quebec, Canada